Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer
- PMID: 32402168
- DOI: 10.1056/NEJMe2004851
Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer
Comment on
-
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. N Engl J Med. 2020. PMID: 32402160 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical